Trial In Progress: A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41).
- Citation:
- Blood vol 138 (Supplement 1) 4776
- Meeting Instance:
- ASH 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Janssen, Takeda, Celgene
- Grants:
- Corr. Author:
- Authors:
- Elizabeth O'Donnell Vera Suman Susan Geyer Omar Nadeem Shira Dinner Andrew J . Yee Jacob Laubach Clifton Mo Sascha Tuchman Kristen Donadio Sarah Sinclair Noopur Raje Paul Richardson
- Networks:
- LAPS-IL036, LAPS-MA036, LAPS-NC007, ME040
- Study
- AFT-41
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: